

contato@inovamedical.com.br www.inovamedical.com.br

Cost-Effectiveness Evaluations of CAR-T Cell Therapies in Health Technology

1- HTA Unit, Inova Medical, Porto Alegre, Brazil. 2- Hospital Moinhos de Vento, Porto Alegre, Brazil.

Background

- \succ The advancement of cellular therapies, suc therapies, are a pivotal stride in the treatment o by the important efficacy observed in clinical stu
- The substantial cost associated with cellular the into healthcare systems and their economic sus

Objective

To identify and characterize cost-effectiveness evaluations for incorporating CAR-T cell therapies in different countries.

Methods

Cost-effectiveness evaluations obtained from health technology assessment agencies (July/2023): > Australia (MSAC); Canada (CADTH); France (HAS); Scotland (SMC); United Kingdom (NICE) The protocol for this review is registered and available online (doi: 10.17605/OSF.IO/95ACK).

Results

- \succ Twenty-nine evaluations were identified for incorporating five CAR-T therapies: axicabtagene tisagenlecleucel (MSAC, CADTH, HAS, SMC, NICE).
- \succ These therapies were assessed for eight types of lymphomas or leukemias, most frequent conditions:
 - \succ Diffuse large B-cell lymphoma (14 evaluations);
 - \succ Acute lymphoblastic leukemia (7 evaluations);
- > Common comparators: rescue chemotherapy and allogeneic hematopoietic stem cell transplantation.
- \succ Twenty-three (79%) evaluations received favorable incorporation recommendations.


Assessment Agencies

Gilson Dorneles^{1,2}; Cíntia Araújo^{1,2}; Nayê Balzan Schneider¹; Maicon Falavigna¹

ch as chimeric antigen receptor (CAR) cell	
of various hematologic conditions, as evidenced	
udies.	
herapies poses a challenge to their integration	
stainability.	

```
ciloleucel (MSAC, CADTH, HAS, SMC, NICE), brexucabtagene autoleucel (MSAC, HAS,
CADTH, SMC, NICE), ciltacabtagene autoleucel (MSAC), idecabtagene vicleucel (CADTH),
```

igure 1. Heat map indicating the ICER value of C eimbursement proposals submitted to different nation Not



Standardized value in US dollars (08/2023): 1 EUR = 1,06 USD; 1 CAD = 0,74 USD; 1 AUD = 0,64 USD; 1 GBP = 1,23 USD

Conclusions

This study emphasized the growing international prominence of CAR-T cell therapies. Despite the high ICER associated with these therapies, 79% of the analyses favored incorporation. Implementing CAR-T therapies presents challenges, especially their high cost, prompting discussions on financing mechanisms for integration into healthcare systems.

Funding: This study received funding from Novartis Biociências Brazil. The authors declare that the sponsor had no role in the study design, data collection and analysis, decision to publish, or preparation of the results.



CAR-T cell therapy evaluated in						
nal agencies.						
Conditional recommentation Recommended						
l		62,716		490,000		
	164,544					
_		294,275		450,000		
4		224,141				
4		119,731		410,000		
4		494,113		,		
╉		158,794		370,000		
		154,167				
		120,304		330,000		
		117,300				
		199,429	-	290,000		
		309,280				
4		310,357		250,000		
4		59,638				
4	60,335			210,000		
4	53,804					
	53,587			170,000		
T		31,852		400.000		
		31,852		130,000		
		29,875		~~ ~~~		
		46,452		90,000		
╡		31,852				
╡		28,666		50,000		
╡		27,387				
		35,293		10,000		